These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16518340)

  • 1. Leptin and inflammation-associated cachexia in chronic kidney disease.
    Mak RH; Cheung W; Cone RD; Marks DL
    Kidney Int; 2006 Mar; 69(5):794-7. PubMed ID: 16518340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of leptin and melanocortin signaling in uremia-associated cachexia.
    Cheung W; Yu PX; Little BM; Cone RD; Marks DL; Mak RH
    J Clin Invest; 2005 Jun; 115(6):1659-65. PubMed ID: 15931394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease.
    Mak RH; Cheung W; Cone RD; Marks DL
    Pediatr Nephrol; 2005 Mar; 20(3):427-31. PubMed ID: 15662537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting the therapeutic potential of leptin signaling in cachexia.
    Mak RH; Cheung WW; Gertler A
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):352-7. PubMed ID: 25259544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice.
    Cheung WW; Ding W; Gunta SS; Gu Y; Tabakman R; Klapper LN; Gertler A; Mak RH
    J Am Soc Nephrol; 2014 Jan; 25(1):119-28. PubMed ID: 24115476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of melanocortin signaling in neuroendocrine and metabolic actions of leptin in male rats with uncontrolled diabetes.
    Meek TH; Matsen ME; Damian V; Cubelo A; Chua SC; Morton GJ
    Endocrinology; 2014 Nov; 155(11):4157-67. PubMed ID: 25137027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin.
    Rahmouni K; Haynes WG; Morgan DA; Mark AL
    J Neurosci; 2003 Jul; 23(14):5998-6004. PubMed ID: 12853417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice.
    Cheung WW; Kuo HJ; Markison S; Chen C; Foster AC; Marks DL; Mak RH
    J Am Soc Nephrol; 2007 Sep; 18(9):2517-24. PubMed ID: 17687077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation and cachexia in chronic kidney disease.
    Cheung WW; Paik KH; Mak RH
    Pediatr Nephrol; 2010 Apr; 25(4):711-24. PubMed ID: 20111974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energy homeostasis and cachexia in chronic kidney disease.
    Mak RH; Cheung W
    Pediatr Nephrol; 2006 Dec; 21(12):1807-14. PubMed ID: 16897005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptin and melanocortin signaling in the hypothalamus.
    Bjørbaek C; Hollenberg AN
    Vitam Horm; 2002; 65():281-311. PubMed ID: 12481551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia.
    Mak RH; Cheung W; Cone RD; Marks DL
    Nat Clin Pract Nephrol; 2006 Sep; 2(9):527-34. PubMed ID: 16941045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of melanocortin signaling ameliorates uremic cachexia.
    Cheung WW; Rosengren S; Boyle DL; Mak RH
    Kidney Int; 2008 Jul; 74(2):180-6. PubMed ID: 18432186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action.
    Ebihara K; Ogawa Y; Katsuura G; Numata Y; Masuzaki H; Satoh N; Tamaki M; Yoshioka T; Hayase M; Matsuoka N; Aizawa-Abe M; Yoshimasa Y; Nakao K
    Diabetes; 1999 Oct; 48(10):2028-33. PubMed ID: 10512369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.
    Cheung WW; Mak RH
    Am J Physiol Renal Physiol; 2012 Nov; 303(9):F1315-24. PubMed ID: 22914778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential role of melanocortins in mediating leptin's central effects on feeding and reproduction.
    Hohmann JG; Teal TH; Clifton DK; Davis J; Hruby VJ; Han G; Steiner RA
    Am J Physiol Regul Integr Comp Physiol; 2000 Jan; 278(1):R50-9. PubMed ID: 10644621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The leptin-dependent and -independent melanocortin signaling system: regulation of feeding and energy expenditure.
    Shimizu H; Inoue K; Mori M
    J Endocrinol; 2007 Apr; 193(1):1-9. PubMed ID: 17400797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin signaling, adiposity, and energy balance.
    Jéquier E
    Ann N Y Acad Sci; 2002 Jun; 967():379-88. PubMed ID: 12079865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of Potent Leptin Receptor Antagonists and Their Therapeutic Use in Mouse Models of Uremic Cachexia and Kidney Fibrosis.
    Mak RH; Cheung WW; Solomon G; Gertler A
    Curr Pharm Des; 2018; 24(9):1012-1018. PubMed ID: 29366406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
    Joppa MA; Gogas KR; Foster AC; Markison S
    Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.